China Medical System Holdings Limited (CMS) has announced a robust financial performance for the first half of 2025, with turnover rising by 10.8% to RMB4,002 million compared to the same period last year. The company’s gross profit also saw an increase of 7.2%, reaching RMB2,891.9 million, whilst profit for the period climbed 3.1% to RMB931.5 million.
The growth is attributed to the diminishing negative impact of National VBP products and the continued sales increase of CMS’s major exclusive and branded products, which contributed 62.1% of total revenue. The company has been advancing its “New CMS, New Ascent” strategy, focusing on the commercialisation of innovative products and expanding into new retail and consumer healthcare sectors.
Key developments include the approval of five innovative drugs, with three NDAs under review, and the addition of two new collaborative R&D products. Notably, CMS completed its secondary listing on the Singapore Exchange in July 2025, enhancing its brand presence in Southeast Asia and international markets.
The company declared an interim dividend per share of RMB0.1555, marking a 3.2% increase from the previous year. As of 30 June 2025, CMS reported bank balances and cash amounting to RMB3,454.1 million, underscoring its strong financial position. The resignation of a non-executive director was also announced, though further details were not disclosed.
“`
